<DOC>
	<DOCNO>NCT01646515</DOCNO>
	<brief_summary>The purpose study determine udenafil improves exercise tolerance patient systolic heart failure .</brief_summary>
	<brief_title>Udenafil Therapy Improve Symptomatology , Exercise Tolerance Hemodynamics Patients With Chronic Systolic Heart Failure</brief_title>
	<detailed_description>Udenafil ( Zydena ) , newly develop PDE-5 inhibitor , prove similar efficacy safety profile , compare PDE-5 inhibitor . Also , laboratory data show udenafil inhibits ventricular hypertrophy fibrosis rat heart failure model . Based result , investigator hypothesize udenafil would improve symptom , exercise capacity hemodynamic status patient systolic heart failure . In 12-week , randomize , double-blind , placebo-controlled trial , patient systolic heart failure enrol accord eligibility criterion . After randomization , study participant assign receive either 50mg udenafil placebo two time day 4 week , dosage double 100mg two time day next 8 week . Participants attend study visit baseline week 4 12 . Physical examination , medical history review , blood sample collection electrocardiogram conduct study visit . At baseline week 12 , participant undergo cardiopulmonary exercise test exercise echocardiography . At every study visit , researcher collect health information .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Systolic</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>â‰¥ 18 year age , LV EF &lt; 40 % longterm use medication inhibit cytochrome P450 3A4 . inability patient exercise test primary pulmonary artery hypertension severe hypotension ( &lt; 90/50mmHg ) severe hypertension ( &gt; 170/100mmHg )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>systolic heart failure</keyword>
	<keyword>udenafil</keyword>
	<keyword>exercise capacity</keyword>
</DOC>